Up­dat­ed: Roche’s Genen­tech wades in­to ra­dio­phar­ma­ceu­ti­cals with Pep­tiDream al­liance, $40M up­front

In one of its first for­ays in­to ra­dio­phar­ma­ceu­ti­cals, Roche’s Genen­tech has lined up a dis­cov­ery and de­vel­op­ment pact with the pep­tide spe­cial­ists at Pep­tiDream.

Genen­tech is hand­ing over $40 mil­lion up­front to kick off the deal, which will fo­cus on macro­cyclic pep­tide can­di­dates against tar­gets of its choice to cre­ate pep­tide-ra­dioiso­tope con­ju­gates. Pep­tiDream will han­dle ear­ly pre­clin­i­cal de­vel­op­ment of any re­sult­ing can­di­dates be­fore send­ing them back to Genen­tech — while keep­ing Japan rights.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.